Magnetic resonance elastography and transient elastography as non-invasive analyses for liver fibrosis: Can they obviate the need for liver biopsy in psoriasis patients treated with methotrexate?

International Journal of Dermatology

Volumn 54, Issue 7, 2015, Pages 752-756

  Kaffenberger, Benjamin H ^a   Kaffenberger, Jessica A ^a   Wong, Henry ^a   Jarjour, Wael ^a   Levin, Douglas ^a   Bechtel, Mark A ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; DERMATOLOGICAL AGENT;

AREA UNDER THE CURVE; ARTICLE; CLINICAL EFFECTIVENESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG MONITORING; ELASTOGRAPHY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAGNETIC RESONANCE ELASTOGRAPHY; MORBIDITY; MORTALITY; PSORIASIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSIENT ELASTOGRAPHY; BIOPSY; CHEMICALLY INDUCED; LIVER; LIVER CIRRHOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES;

BIOPSY; DERMATOLOGIC AGENTS; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; METHOTREXATE; PSORIASIS;

EID: 84932108532     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12923     Document Type: Article

References (36)

1. Roenigk HH Jr, Auerbach R, Maibach HI, et al. Methotrexate guidelines - revised. J Am Acad Dermatol 1982; 6: 145-155.
2. Roenigk HR Jr, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145-156.
3. Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-837.
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-485.
5. Kremer JM, Alarcón GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37: 316-328.
6. Erickson A, Reddy V, Vogelgesang S, et al. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995; 38: 1115-1119.
7. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-483.
8. Barker J, Horn EJ, Lebwohl M, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011; 25: 758-764.
9. Maharaj B, Maharaj R, Leary W, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 8: 1982-1984.
10. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618.
11. Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
12. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
13. Berends MA, van Oijen MG, Snoek J, et al. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis. Arch Dermatol 2007; 143: 1515-1519.
14. Aithal GP, Haugk B, Das S, et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther 2004; 19: 391-399.
15. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy: a multicenter retrospective study on 68, 276 biopsies. J Hepatol 1986; 50: 165-173.
16. West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology 2010; 139: 1230-1237.
17. Lindor KD, Bru C, Jorgensen RA, et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996; 23: 1079-1083.
18. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-481.
19. Muthupillai R, Lomas D, Rossman P, et al. Waves magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science 1995; 269: 1854-1857.
20. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135: 32-40.
21. Huwart L, Sempoux C, Salameh N, et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 2007; 245: 458-466.
22. Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5: 1207.e2-1213.e2.
23. Asbach P, Klatt D, Schlosser B, et al. Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography 1. Radiology 2010; 257: 80-86.
24. Wang Y, Ganger DR, Levitsky J, et al. Assessment of chronic hepatitis and fibrosis: comparison of magnetic resonance elastography (MRE) and diffusion-weighted imaging (DWI). AJR Am J Roentgenol 2011; 196: 553-561.
25. Wang Q-BQ, Zhu H, Liu HH-L, Zhang B. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: a meta-analysis. Hepatology 2012; 56: 239-247.
26. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-1293.
27. Mehta S, Lau B, Afdhal N, et al. Exceeding the limits of liver histology markers. J Hepatol 2009; 50: 36-41.
28. Bray AP, Barnova I, Przemioslo R, et al. Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy. Br J Dermatol 2012; 166: 1125-1127.
29. Friedrich-Rust M, Ong M-F, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974.
30. Park S-H, Choe J-Y, Kim S-K. Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine 2010; 77: 588-592.
31. ®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol 2012; 47: 575-579.
32. Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol 2010; 53: 1035-1040.
33. Barbero-Villares A, Mendoza J, Trapero-Marugan M, et al. Evaluation of liver fibrosis by transient elastography in methotrexate-treated patients. Med Clin (Barc) 2011; 137: 637-639.
34. Montaudié H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011; 25(Suppl. 2): 12-18.
35. Chládek J, Simková M, Vanecková J, et al. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers. J Eur Acad Dermatol Venereol 2013; 27: 1007-1014.
36. Rockey DC. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 2008; 134: 8-14.